Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Metformin; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTATA-MP
  • Sponsors Janssen Research & Development

Most Recent Events

  • 18 Mar 2019 Time matched evaluation of cardiovascular risk associated with drugs using 10 trials (EXAMINE, SAVOR TIMI 53, TECOS, ELIXA, LEADEER, SUSTAIN-6, EXSCEL, EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58); results published in the Clinical Drug Investigation
  • 15 Sep 2017 Results of a post-hoc analysis assessing the effect of Canagliflozin on liver function tests and liver fibrosis in patients from four phase III trials (CANTATA-M, CANTATA-MSU, CANTATA-D and CANTATA-MP) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
  • 01 Apr 2017 Pooled results of a post hoc analysis assessing the effects of canagliflozin on serum magnesium in hypomagnesemic patients from four placebo-controlled studies (CANTATA-MP, CANTATA-M, CANTATA-MSU, and CANTATA-D; n=2313) published in the Diabetes Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top